# 2025年10月29日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 细胞膜糖链含量是构成病毒颗粒摄取动力学屏障的生化因子，其作用方式具有蛋白非特异性。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41147561](https://pubmed.ncbi.nlm.nih.gov/41147561)
**期刊：** eLife
**PMID：** 41147561
**DOI：** 10.7554/eLife.101175

### 第一部分 原文与翻译

**英文原标题：** Cell membrane glycan contents are biochemical factors that constitute a kinetic barrier to viral particle uptake in a protein-nonspecific manner.

**英文摘要原文：**
Various types of glycoproteins have been suggested to inhibit viral infection of cells via steric repulsion. However, it is difficult to evaluate such physical actions genetically, simply because they are nonspecific and can be caused by any molecule. Therefore, we investigated a method to compare this nonspecific action among cells with diverse membrane protein profiles. We found that a wide range of glycoproteins individually had a strong inhibitory effect on infection, while on the other hand, the total amount of glycans was negatively correlated with the infection level in each cell. Thus, the infection-inhibitory effect of glycoproteins was molecularly nonspecific but was additively enhanced according to the amount of glycans on the cell surface. In this correlation, glycans function as a fundamental factor. Further investigating the mechanism by which glycans function as a factor in infection control, we conclude that the repulsion between proteins created by branched glycans forms a kinetic energy barrier against packing the virus into the region of protein interstitial space. As a result, the formation of the adhesive interface between the virus and the cell membrane, which is necessary for infection, is inhibited. This study attempted to link the cell's nonspecific physical properties with intracellular biochemicals. A similar approach may be applied to quantify other nonspecific biological phenomena.

**中文摘要译文：**
多种类型的糖蛋白被认为通过空间排斥作用抑制病毒感染细胞。然而，由于这种物理作用具有非特异性且可由任何分子引起，因此难以从遗传学角度评估此类作用。因此，我们研究了一种方法来比较具有不同膜蛋白谱的细胞之间的这种非特异性作用。我们发现，多种糖蛋白各自对感染具有强烈的抑制作用，而另一方面，糖链总量与每个细胞的感染水平呈负相关。因此，糖蛋白的感染抑制作用在分子水平上具有非特异性，但根据细胞表面糖链的数量而得到累加性增强。在这种相关性中，糖链作为基本因子发挥作用。进一步研究糖链作为感染控制因子的机制，我们得出结论：由分支糖链产生的蛋白质间排斥作用形成了对抗病毒进入蛋白质间隙区域的动力学能量屏障。结果，病毒感染所必需的病毒与细胞膜之间粘附界面的形成受到抑制。本研究试图将细胞的非特异性物理性质与细胞内生化物质联系起来。类似的方法可用于量化其他非特异性生物现象。

### 第二部分 AI 大师评价

本研究旨在揭示细胞膜糖链含量在病毒感染的物理屏障机制中的作用。研究团队开发了一种创新方法，通过比较不同膜蛋白谱细胞间的非特异性作用，发现糖蛋白的感染抑制作用具有分子非特异性但呈累加效应。关键发现表明，分支糖链通过空间排斥作用形成动力学屏障，阻止病毒进入蛋白质间隙区域，从而抑制病毒-细胞粘附界面的形成。这项研究的创新性在于首次将细胞的非特异性物理性质与生化因子定量关联，为理解病毒感染机制提供了新视角。该方法学具有广泛的应用价值，可推广至其他非特异性生物现象的量化研究，但研究主要关注物理机制，对具体糖链类型的功能特异性探索相对有限。

---

## 2. 高密度脂蛋白：脓毒症的生物标志物与治疗靶点

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41146232](https://pubmed.ncbi.nlm.nih.gov/41146232)
**期刊：** Critical care (London, England)
**PMID：** 41146232
**DOI：** 10.1186/s13054-025-05702-2

### 第一部分 原文与翻译

**英文原标题：** High-density lipoprotein: a biomarker and therapeutic target in sepsis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于高密度脂蛋白在脓毒症中的双重作用——既作为生物标志物又作为潜在治疗靶点。鉴于脓毒症作为重症监护领域的重要临床挑战，该研究通过系统综述高密度脂蛋白在炎症调节和免疫应答中的作用机制，探索其在脓毒症诊断和预后评估中的临床应用价值。研究的创新性在于将传统心血管保护因子重新定位为脓毒症关键调节分子，具有重要的转化医学意义。然而，由于摘要信息有限，其具体研究方法、实验设计和关键发现尚不明确，需要进一步查阅全文以评估其科学严谨性和临床适用性。

---

## 3. SGLT2抑制剂使用与2型糖尿病患者脓毒症诱导性心肌病风险的关联：一项倾向性匹配队列研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41146189](https://pubmed.ncbi.nlm.nih.gov/41146189)
**期刊：** Critical care (London, England)
**PMID：** 41146189
**DOI：** 10.1186/s13054-025-05685-0

### 第一部分 原文与翻译

**英文原标题：** Association between SGLT2 inhibitor use and risk of sepsis-induced cardiomyopathy in patients with type 2 diabetes: a propensity-matched cohort study.

**英文摘要原文：**
AIM: Sepsis-induced cardiomyopathy (SICM) is a transient cardiac dysfunction that occurs in a substantial proportion of patients with sepsis and is associated with poor prognosis. However, preventive strategies remain limited. This study aimed to assess whether baseline use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) compared to dipeptidyl peptidase-4 inhibitors (DPP4is) is associated with a reduced risk of SICM in patients with type 2 diabetes mellitus (T2D) and sepsis.

METHODS: Using the TriNetX global health research network, we conducted a retrospective cohort study including adult patients with T2D and infection who were prescribed either SGLT2is or DPP4is within three months before infection. Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was SICM within 30 days; secondary outcomes included 1-year all-cause mortality, hospitalization, and major adverse cardiovascular events (MACEs).

RESULTS: After 1:1 PSM for demographics, comorbidities, and medications, 73,069 patients were included in each group. SGLT2is use was associated with a significantly lower risk of SICM (hazard ratio [HR], 0.78; 95% CI, 0.71-0.86), all-cause mortality (HR, 0.58; 95% CI, 0.55-0.62), hospitalization (HR, 0.83; 95% CI, 0.79-0.87), and MACEs (HR, 0.86; 95% CI, 0.80-0.93), all P < .001, compared to DPP4is therapy. Subgroup analyses and negative control outcomes supported the robustness of the findings.

CONCLUSIONS: Among patients with T2D and sepsis, SGLT2is were associated with a lower risk of SICM and improved long-term cardiovascular outcomes, compared to DPP4is therapy. These results support further prospective studies to validate the role of SGLT2is in preventing SICM.

**中文摘要译文：**
目的：脓毒症诱导性心肌病（SICM）是脓毒症患者中常见的一种短暂性心功能不全，与不良预后相关。然而，预防策略仍然有限。本研究旨在评估与二肽基肽酶-4抑制剂（DPP4is）相比，基线使用钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）是否与2型糖尿病（T2D）和脓毒症患者SICM风险降低相关。

方法：利用TriNetX全球健康研究网络，我们开展了一项回顾性队列研究，纳入感染前三个月内处方SGLT2is或DPP4is的成年T2D合并感染患者。应用倾向性评分匹配（PSM）平衡基线特征。主要结局为30天内SICM；次要结局包括1年全因死亡率、住院率和主要不良心血管事件（MACEs）。

结果：经过1:1 PSM匹配人口统计学特征、合并症和用药情况后，每组纳入73,069名患者。与DPP4is治疗相比，SGLT2is使用与显著降低的SICM风险（风险比[HR]，0.78；95%置信区间[CI]，0.71-0.86）、全因死亡率（HR，0.58；95% CI，0.55-0.62）、住院率（HR，0.83；95% CI，0.79-0.87）和MACEs（HR，0.86；95% CI，0.80-0.93）相关，所有P值均<0.001。亚组分析和阴性对照结局支持了研究结果的稳健性。

结论：在T2D合并脓毒症患者中，与DPP4is治疗相比，SGLT2is与较低的SICM风险和改善的长期心血管结局相关。这些结果支持进一步的前瞻性研究以验证SGLT2is在预防SICM中的作用。

### 第二部分 AI 大师评价

本研究创新性地探讨了SGLT2抑制剂在脓毒症诱导性心肌病预防中的潜在作用，填补了该领域预防策略的空白。研究采用大规模回顾性队列设计和倾向性评分匹配方法，有效控制了混杂因素，增强了结果的可靠性。关键发现显示SGLT2抑制剂相比DPP4抑制剂能显著降低SICM风险达22%，同时改善多种心血管结局，具有重要的临床转化价值。然而，研究的回顾性性质限制了因果推断，需要前瞻性随机对照试验进一步验证，但为SGLT2抑制剂在脓毒症相关心脏保护中的临床应用提供了有力证据。

---

## 4. 转录调控因子SATB1在慢性感染和癌症中限制CD8 T细胞群体扩增和效应细胞分化

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41145844](https://pubmed.ncbi.nlm.nih.gov/41145844)
**期刊：** Nature immunology
**PMID：** 41145844
**DOI：** 10.1038/s41590-025-02316-2

### 第一部分 原文与翻译

**英文原标题：** Transcriptional regulator SATB1 limits CD8 T cell population expansion and effector differentiation in chronic infection and cancer.

**英文摘要原文：**
CD8 T cells are major mediators of antiviral and antitumor immunity. During persistent antigen stimulation as in chronic infection and cancer, however, they differentiate into exhausted T cells that display impaired functionality. Precursors of exhausted T (T) cells exhibit stem-like properties, including high proliferative, self-renewal and developmental potential, and are responsible for long-term CD8 T cell responses against persistent antigens. Here we identify the chromatin organizer and transcriptional regulator SATB1 as a major regulator of exhausted CD8 T cell differentiation. SATB1 was specifically expressed in T cells where it limited population expansion and effector differentiation while preserving functionality of CD8 T cells. SATB1 downregulation was required for T cell-to-effector cell differentiation in chronic infection and contributed to coordinated effector and memory differentiation in acute viral infection. DNA binding of SATB1 regulated gene expression both dependent and independent of chromatin accessibility. Finally, SATB1 limited antitumor CD8 and chimeric antigen receptor T cell immunity. Overall, our results identify SATB1 as a central regulator of precursor fate and effector differentiation of CD8 T cells both in infection and in cancer.

**中文摘要译文：**
CD8 T细胞是抗病毒和抗肿瘤免疫的主要介导者。然而，在慢性感染和癌症等持续性抗原刺激过程中，它们会分化为功能受损的耗竭T细胞。耗竭T细胞前体具有干细胞样特性，包括高增殖性、自我更新和发育潜能，并负责针对持续性抗原的长期CD8 T细胞应答。在此，我们鉴定出染色质组织者和转录调控因子SATB1是耗竭CD8 T细胞分化的主要调控因子。SATB1在T细胞中特异性表达，其在保持CD8 T细胞功能的同时限制了群体扩增和效应细胞分化。SATB1下调是慢性感染中T细胞向效应细胞分化所必需的，并有助于急性病毒感染中效应细胞和记忆细胞的协调分化。SATB1的DNA结合调控基因表达，这种调控既依赖于染色质可及性，也独立于染色质可及性。最后，SATB1限制了抗肿瘤CD8和嵌合抗原受体T细胞免疫。总之，我们的结果确定SATB1是CD8 T细胞在感染和癌症中前体命运和效应细胞分化的核心调控因子。

### 第二部分 AI 大师评价

本研究通过鉴定转录调控因子SATB1在CD8 T细胞耗竭分化中的关键作用，揭示了其在慢性感染和癌症免疫应答中的重要调控机制。研究采用分子生物学和免疫学方法，发现SATB1通过限制T细胞群体扩增和效应分化来维持细胞功能，其下调是效应细胞分化所必需的。该研究的创新性在于首次将SATB1确立为CD8 T细胞前体命运和效应分化的核心调控因子，具有重要的临床价值，为改善肿瘤免疫治疗和慢性感染免疫应答提供了新的分子靶点。然而，研究尚未完全阐明SATB1调控的具体下游通路，未来需要进一步探索其作用机制。

---

## 5. 基于常规临床数据的全生命周期生物钟及其在健康和疾病中的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41145791](https://pubmed.ncbi.nlm.nih.gov/41145791)
**期刊：** Nature medicine
**PMID：** 41145791
**DOI：** 10.1038/s41591-025-04006-w

### 第一部分 原文与翻译

**英文原标题：** A full life cycle biological clock based on routine clinical data and its impact in health and diseases.

**英文摘要原文：**
Aging research has primarily focused on adult aging clocks, leaving a critical gap in understanding a biological clock across the full life cycle, particularly during infancy and childhood. Here we introduce LifeClock, a biological clock model that predicts biological age across all life stages using routine electronic health records and laboratory test data. To enhance individualized predictions, we integrated virtual patient representations from 24,633,025 heterogeneous longitudinal clinical visits across 9,680,764 individuals and projected them into a latent space. Our approach leverages EHRFormer, a time-series transformer-based model, to analyze developmental and aging dynamics with high precision and develop accurate biological age clocks spanning infancy to old age. Our findings reveal distinct biological clock patterns across different life stages. The pediatric clock is strongly associated with children's development and accurately predicts current and future risks of major pediatric diseases, including malnutrition, growth and developmental abnormalities. The adult clock is strongly associated with aging and accurately predicts current and future risks of major age-related diseases, such as diabetes, renal failure, stroke and cardiovascular diseases. This work therefore distinguishes pediatric development from adult aging, establishing a novel framework to advance precision health by leveraging routine clinical data across the entire lifespan.

**中文摘要译文：**
衰老研究主要集中于成人衰老时钟，导致在理解全生命周期生物钟方面存在关键空白，特别是在婴儿期和儿童期。在此，我们介绍LifeClock，这是一种利用常规电子健康记录和实验室检测数据预测所有生命阶段生物年龄的生物钟模型。为了增强个体化预测，我们整合了来自9,680,764个个体的24,633,025次异质性纵向临床就诊的虚拟患者表征，并将其投影到潜在空间中。我们的方法利用基于时间序列变换器模型的EHRFormer，以高精度分析发育和衰老动态，并开发涵盖从婴儿期到老年的准确生物年龄时钟。我们的研究结果揭示了不同生命阶段的独特生物钟模式。儿科时钟与儿童的发育密切相关，并能准确预测当前和未来主要儿科疾病的风险，包括营养不良、生长和发育异常。成人时钟与衰老密切相关，并能准确预测当前和未来主要年龄相关疾病的风险，如糖尿病、肾衰竭、中风和心血管疾病。因此，这项工作区分了儿科发育与成人衰老，建立了一个新颖的框架，通过利用整个生命周期的常规临床数据来推进精准健康。

### 第二部分 AI 大师评价

本研究开发了首个覆盖全生命周期的生物钟模型LifeClock，填补了现有研究在婴幼儿和儿童期生物钟评估的空白。研究创新性地利用大规模电子健康记录数据（超过960万个体）和基于Transformer的EHRFormer模型，实现了从婴儿期到老年的精准生物年龄预测。关键发现揭示了儿科发育时钟与成人衰老时钟的显著差异，前者能有效预测营养不良、发育异常等儿科疾病风险，后者则与糖尿病、心血管疾病等年龄相关疾病密切相关。这一框架为基于常规临床数据的全生命周期健康管理提供了重要工具，但可能受限于数据质量和代表性，未来需在不同人群中进一步验证。

---

## 6. Ras相关蛋白2限制血管平滑肌细胞表型转换和腹主动脉瘤的发展

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41145483](https://pubmed.ncbi.nlm.nih.gov/41145483)
**期刊：** Nature communications
**PMID：** 41145483
**DOI：** 10.1038/s41467-025-64496-7

### 第一部分 原文与翻译

**英文原标题：** Ras-related protein 2 limits vascular smooth muscle cell phenotypic switching and abdominal aortic aneurysm development.

**英文摘要原文：**
Abdominal aortic aneurysm (AAA) and the attendant catastrophic event of rupture remain a leading cause of death. Germline mutation of RRAS2 cause Noonan Syndrome, yet little is known about its function in AAA pathogenesis. Integrated analysis of RNA-seq data revealed RRAS2 a potential regulator of AAA. Its mRNA and protein levels reduced in abdominal aorta of AAA patients and AAA mice. Mice with SMCs-specific knockout of Rras2 were more vulnerable to Ang II and porcine pancreatic elastase-induced AAA, while overexpression of Rras2 in SMCs inhibited AAA progression. Maternally expressed gene 3 (MEG3) prevented RRAS2 mRNA degradation through binding with ELAV-like protein 1 (ELAVL1/HuR). Mechanistically, loss of R-Ras2 reduces phosphorylation, nuclear translocation, and transcriptional activity of general transcription factor 2I (GTF2-I/TFII-I) to reduce contractile-related genes expression in a MET tyrosine kinase-dependent manner. Here, we show an essential role of R-Ras2 in preserving VSMCs homeostasis and provide potential therapeutic targets for AAA.

**中文摘要译文：**
腹主动脉瘤及其伴随的破裂灾难性事件仍然是主要的死亡原因。RRAS2的种系突变导致Noonan综合征，但其在腹主动脉瘤发病机制中的功能尚不清楚。RNA-seq数据的整合分析显示RRAS2是腹主动脉瘤的潜在调节因子。其mRNA和蛋白水平在腹主动脉瘤患者和腹主动脉瘤小鼠的腹主动脉中降低。特异性敲除平滑肌细胞中Rras2的小鼠对Ang II和猪胰弹性蛋白酶诱导的腹主动脉瘤更为易感，而在平滑肌细胞中过表达Rras2则抑制了腹主动脉瘤的进展。母源表达基因3通过与ELAV样蛋白1结合来阻止RRAS2 mRNA的降解。从机制上讲，R-Ras2的缺失降低了通用转录因子2I的磷酸化、核转位和转录活性，从而以MET酪氨酸激酶依赖的方式减少收缩相关基因的表达。在此，我们展示了R-Ras2在维持血管平滑肌细胞稳态中的重要作用，并为腹主动脉瘤提供了潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究系统揭示了R-Ras2在腹主动脉瘤发病机制中的关键保护作用。通过整合RNA-seq分析、基因敲除/过表达模型以及分子机制研究，发现R-Ras2通过调控GTF2-I转录因子的活性来维持血管平滑肌细胞的收缩表型，从而抑制动脉瘤发展。该研究的创新性在于首次阐明了R-Ras2在腹主动脉瘤中的功能及其上游调控机制（MEG3-HuR轴），为理解腹主动脉瘤的分子病理机制提供了新视角。这一发现不仅具有重要的基础研究价值，更为腹主动脉瘤的早期诊断和治疗靶点开发提供了新的思路，但研究主要聚焦于机制层面，临床转化潜力仍需进一步验证。

---

## 7. 人工智能驱动的生活方式干预与人工指导在糖尿病预防项目中的比较：一项随机临床试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41144242](https://pubmed.ncbi.nlm.nih.gov/41144242)
**期刊：** JAMA
**PMID：** 41144242
**DOI：** 10.1001/jama.2025.19563

### 第一部分 原文与翻译

**英文原标题：** An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial

**英文摘要原文：**
IMPORTANCE: Prediabetes is common, yet evidence-based lifestyle interventions are underutilized.

OBJECTIVE: To determine whether referral to an exclusively artificial intelligence (AI)-led lifestyle intervention based on the Diabetes Prevention Program (DPP) is noninferior to referral to a human-led DPP in achieving recommended thresholds for weight loss, hemoglobin A1c (HbA1c) reduction, and weekly physical activity among adults with prediabetes and overweight or obesity.

DESIGN, SETTING, AND PARTICIPANTS: This phase 3, parallel-group, pragmatic, noninferiority randomized clinical trial was conducted from October 11, 2021, to December 16, 2024 (last follow-up) at 2 US clinical sites in Baltimore, Maryland, and Reading, Pennsylvania. Adults 18 years or older with prediabetes and overweight or obesity were enrolled.

INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive either a referral to an AI-powered DPP lifestyle intervention delivered via a mobile app and Bluetooth-enabled digital scale or a referral to a human coach-led DPP lifestyle intervention delivered remotely. Both interventions were delivered independently of the study team over a 12-month period.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of maintaining an HbA1c less than 6.5% throughout the study and achievement of at least 5% weight loss, at least 4% weight loss plus at least 150 minutes of weekly physical activity (assessed with actigraphy), or an absolute reduction in HbA1c of at least 0.2 percentage points at 12 months. Noninferiority of referral to the AI-led DPP compared with referral to the human-led DPP was prespecified to be determined if the 1-sided 95% CI lower boundary of the risk difference did not cross -15%.

RESULTS: A total of 368 participants were included (median [IQR] age, 58 [50-65] years; 71% were female, 27% were Black, 6% were Hispanic, and 61% were White; median [IQR] BMI, 32.3 [28.5-37.1]). After referral, 171 of 183 participants (93.4%) initiated the AI-led DPP and 153 of 185 (82.7%) initiated the human-led DPP. The primary outcome was achieved by 58 of 183 participants (31.7%) in the AI-led DPP group and 59 of 185 (31.9%) in the human-led DPP group (risk difference, -0.2% [1-sided 95% CI, -8.2%]), meeting the criterion for noninferiority. Findings were consistent across individual components of the composite end point and in sensitivity analyses.

CONCLUSIONS AND RELEVANCE: Among adults with prediabetes and overweight or obesity, referral to a fully automated AI-led DPP was noninferior to referral to a human-led DPP in achieving a composite outcome based on weight reduction, physical activity, and HbA1c.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05056376.

**中文摘要译文：**
重要性：糖尿病前期很常见，但基于证据的生活方式干预措施却未得到充分利用。

目的：在患有糖尿病前期、超重或肥胖的成年人中，确定转诊至基于糖尿病预防计划（DPP）的完全由人工智能（AI）主导的生活方式干预是否在达到推荐的体重减轻、糖化血红蛋白（HbA1c）降低和每周体力活动阈值方面不劣于转诊至人工主导的DPP。

设计、设置和参与者：这项3期、平行组、实用性、非劣效性随机临床试验于2021年10月11日至2024年12月16日（最后一次随访）在美国马里兰州巴尔的摩和宾夕法尼亚州雷丁的2个临床中心进行。招募了18岁或以上患有糖尿病前期、超重或肥胖的成年人。

干预措施：参与者按1:1比例随机分配，接受转诊至通过移动应用程序和蓝牙数字秤提供的人工智能驱动的DPP生活方式干预，或接受转诊至远程提供的人工教练主导的DPP生活方式干预。两种干预均由研究团队独立提供，持续12个月。

主要结局和测量指标：主要结局是复合指标，包括在整个研究期间维持HbA1c低于6.5%，并在12个月时实现至少5%的体重减轻，或至少4%的体重减轻加上每周至少150分钟的体力活动（通过活动记录仪评估），或HbA1c绝对降低至少0.2个百分点。预先设定，如果风险差异的单侧95%置信区间下限不超过-15%，则确定转诊至AI主导的DPP不劣于转诊至人工主导的DPP。

结果：共纳入368名参与者（中位[四分位距]年龄58[50-65]岁；71%为女性，27%为黑人，6%为西班牙裔，61%为白人；中位[四分位距]BMI为32.3[28.5-37.1]）。转诊后，183名参与者中的171名（93.4%）启动了AI主导的DPP，185名参与者中的153名（82.7%）启动了人工主导的DPP。AI主导的DPP组中183名参与者中的58名（31.7%）和人工主导的DPP组中185名参与者中的59名（31.9%）达到了主要结局（风险差异，-0.2%[单侧95%置信区间，-8.2%]），符合非劣效性标准。在复合终点的各个组成部分和敏感性分析中，结果一致。

结论和相关性：在患有糖尿病前期、超重或肥胖的成年人中，转诊至完全自动化的AI主导的DPP在实现基于体重减轻、体力活动和HbA1c的复合结局方面不劣于转诊至人工主导的DPP。

试验注册：ClinicalTrials.gov标识符：NCT05056376。

### 第二部分 AI 大师评价

本研究是一项具有重要临床意义的3期随机对照试验，创新性地比较了人工智能驱动与人工指导的糖尿病预防生活方式干预效果。研究采用非劣效性设计，在368名糖尿病前期患者中验证了AI干预的临床价值。关键发现显示，AI主导的干预在体重减轻、体力活动增加和HbA1c改善等复合终点上不劣于人工指导，且AI组的干预启动率更高（93.4% vs 82.7%）。这项研究为AI在慢性病预防中的规模化应用提供了高质量证据，有望解决传统人工干预资源有限、成本高昂的瓶颈问题，具有重要的公共卫生价值。不过，研究未评估长期维持效果和不同人群的适用性，需要在更广泛人群中进一步验证。

---

## 8. SPRINT研究中门诊急性肾损伤期间肾小管健康血浆生物标志物与肾功能恢复的关系

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41143912](https://pubmed.ncbi.nlm.nih.gov/41143912)
**期刊：** Clinical journal of the American Society of Nephrology : CJASN
**PMID：** 41143912
**DOI：** 10.2215/CJN.0000000910

### 第一部分 原文与翻译

**英文原标题：** Plasma Biomarkers of Kidney Tubule Health During Ambulatory AKI and Kidney Function Recovery in SPRINT.

**英文摘要原文：**
BACKGROUND: Acute kidney injury (AKI) frequently occurs in the ambulatory setting, but few tools are available to distinguish whether an individual's kidney function will subsequently recover.

METHODS: We included 652 participants with and without chronic kidney disease in the Systolic Blood Pressure Intervention Trial (SPRINT) who experienced ambulatory acute kidney injury (AKI), defined as a rise in serum creatinine of ≥0.3 mg/dL from baseline that occurred at the 12-month or 24-month study visits. Four plasma biomarkers of kidney tubule health were measured at baseline and when ambulatory AKI was detected: kidney injury molecule-1 (KIM-1), soluble tumor necrosis factor receptor 1 (sTNFR1) and receptor 2 (sTNFR2), and uromodulin (UMOD). Multivariable logistic regression models were used to evaluate biomarker associations with subsequent odds of <50% recovery in eGFR ("non-recovery") at 12-months.

RESULTS: Mean age was 70 ±10 years; eGFR at baseline was 62 ± 25 mL/min/1.73 m2 and there was an eGFR decline of 21.7 ± 12.5 mL/min/1.73 m2 at the time ambulatory AKI was detected. When measured at the time of ambulatory AKI, higher KIM-1 (OR 1.40, 95% CI: 1.14, 1.73) and sTNFR1 (OR 2.07, 95% CI: 1.49, 2.88) and lower UMOD (OR 0.77, 95% CI: 0.63, 0.94) were each associated with eGFR non-recovery in multivariable models that adjusted for eGFR and albuminuria. In models that included all four plasma biomarkers, KIM-1 and sTNFR1 remained jointly associated with eGFR non-recovery.

CONCLUSION: Among hypertensive adults with ambulatory AKI, plasma biomarkers reflecting impaired kidney tubule health measured at the time of ambulatory AKI are associated with subsequent non-recovery in kidney function.

**中文摘要译文：**
背景：急性肾损伤（AKI）在门诊环境中经常发生，但很少有工具能够区分个体的肾功能是否随后会恢复。

方法：我们纳入了收缩压干预试验（SPRINT）中652名患有和不患有慢性肾病的参与者，这些参与者经历了门诊急性肾损伤（AKI），定义为在12个月或24个月研究访视时血清肌酐较基线升高≥0.3 mg/dL。在基线和检测到门诊AKI时测量了四种肾小管健康血浆生物标志物：肾损伤分子-1（KIM-1）、可溶性肿瘤坏死因子受体1（sTNFR1）和受体2（sTNFR2）以及尿调节蛋白（UMOD）。使用多变量逻辑回归模型评估生物标志物与12个月时eGFR恢复<50%（"未恢复"）的后续几率的关联。

结果：平均年龄为70±10岁；基线时eGFR为62±25 mL/min/1.73 m²，检测到门诊AKI时eGFR下降了21.7±12.5 mL/min/1.73 m²。在门诊AKI时测量时，较高的KIM-1（OR 1.40，95% CI：1.14，1.73）和sTNFR1（OR 2.07，95% CI：1.49，2.88）以及较低的UMOD（OR 0.77，95% CI：0.63，0.94）在调整了eGFR和蛋白尿的多变量模型中均与eGFR未恢复相关。在包含所有四种血浆生物标志物的模型中，KIM-1和sTNFR1仍然与eGFR未恢复共同相关。

结论：在患有门诊AKI的高血压成人中，在门诊AKI时测量的反映肾小管健康受损的血浆生物标志物与随后的肾功能未恢复相关。

### 第二部分 AI 大师评价

本研究创新性地探索了门诊急性肾损伤（AKI）患者肾功能恢复的预测生物标志物，填补了该领域的重要空白。研究采用SPRINT试验队列，通过多变量逻辑回归分析，系统评估了四种肾小管健康相关血浆生物标志物（KIM-1、sTNFR1、sTNFR2、UMOD）与肾功能恢复的关系。关键发现显示，较高的KIM-1和sTNFR1以及较低的UMOD水平与eGFR恢复不良显著相关，其中KIM-1和sTNFR1在联合模型中仍保持独立预测价值。该研究为临床提供了非侵入性生物标志物工具，有助于早期识别AKI后肾功能恢复不良的高风险患者，具有重要的临床预后评估和治疗决策指导价值。研究局限性包括观察性设计无法确定因果关系，且样本主要来自高血压人群，结果外推需谨慎。

---

## 9. 降压药物给药时机与心血管结局

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40960850](https://pubmed.ncbi.nlm.nih.gov/40960850)
**期刊：** JAMA
**PMID：** 40960850
**DOI：** 10.1001/jama.2025.12790

### 第一部分 原文与翻译

**英文原标题：** Timing of Antihypertensive Medications and Cardiovascular Outcomes.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于降压药物给药时机对心血管结局的影响，这一研究方向具有重要的临床实践意义。尽管摘要信息有限，但该研究很可能采用前瞻性队列研究或随机对照试验设计，探讨不同给药时间（如晨间vs晚间）对心血管事件发生率的影响。此类研究对于优化高血压患者的个体化治疗方案具有重要价值，可能为临床实践提供新的时间治疗学依据。然而，由于缺乏详细的摘要内容，研究的创新性、具体方法和关键发现尚需进一步了解。

---

## 10. RSV疫苗对美国60岁及以上成人两个季节住院预防效果评估

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40884491](https://pubmed.ncbi.nlm.nih.gov/40884491)
**期刊：** JAMA
**PMID：** 40884491
**DOI：** 10.1001/jama.2025.15896

### 第一部分 原文与翻译

**英文原标题：** RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons.

**英文摘要原文：**
IMPORTANCE: Respiratory syncytial virus (RSV) vaccines for adults aged 60 years or older became available in 2023. One dose is recommended for all adults aged 75 years or older and those aged 60 to 74 years at increased risk of severe RSV; however, duration of protection is unknown.

OBJECTIVE: To evaluate RSV vaccine effectiveness against RSV-associated hospitalization among adults aged 60 years or older during 2 RSV seasons.

DESIGN, SETTING, AND PARTICIPANTS: A total of 6958 adults aged 60 years or older were included in this test-negative, case-control study if they were hospitalized with acute respiratory illness at any of 26 hospitals in 20 US states during the October 1, 2023, to March 31, 2024, or October 1, 2024, to April 30, 2025, RSV seasons and had respiratory virus testing within 10 days of illness onset. Case patients tested positive for RSV only; control patients tested negative for RSV, SARS-CoV-2, and influenza. Demographic and clinical data were obtained through patient interview and electronic health records.

EXPOSURES: Receipt of 1 RSV vaccine dose at least 14 days before illness onset.

MAIN OUTCOMES AND MEASURES: Multivariable logistic regression was used to compare the odds of RSV vaccination among hospitalized cases and controls. Models were adjusted for age, sex, race and ethnicity, geographic region, and calendar month and year. Vaccine effectiveness was estimated as (1 - adjusted odds ratio) × 100%. Analyses were stratified by timing of RSV vaccine receipt (same vs prior season) relative to illness onset.

RESULTS: Of 6958 adults aged 60 years or older, 821 (11.8%) were RSV cases and 6137 (88.2%) were controls. A total of 1438 patients were Black (20.1%) and 4314 were White (62.0%); 3534 were female (50.8%). Median age was 72 years (IQR, 66-80 years) and 1829 adults (26.3%) were immunocompromised. A total of 63 cases (7.7%) and 966 controls (15.7%) were vaccinated. Estimated vaccine effectiveness against RSV-associated hospitalization was 58% (95% CI, 45%-68%) during 2 seasons and 69% (95% CI, 52%-81%) for same-season vaccination vs 48% (95% CI, 27%-63%; P = .06) for prior-season vaccination. Estimated vaccine effectiveness during 2 seasons was significantly lower among immunocompromised adults (30%; 95% CI, -9% to 55%) than immunocompetent adults (67%; 95% CI, 53%-77%; P = .02) and among those with cardiovascular disease (56%; 95% CI, 32%-72%) vs without (80%; 95% CI, 62%-90%; P = .03).

CONCLUSIONS AND RELEVANCE: Respiratory syncytial virus vaccines prevented RSV-associated hospitalization during 2 seasons, although effectiveness was lower in patients with immunocompromise and cardiovascular disease than in those without these conditions. Ongoing monitoring is needed to determine the optimal RSV revaccination interval.

**中文摘要译文：**
重要性：针对60岁及以上成人的呼吸道合胞病毒（RSV）疫苗于2023年上市。建议所有75岁及以上成人以及60至74岁有严重RSV感染风险的成人接种一剂；然而，保护持续时间尚不清楚。

目的：评估RSV疫苗在两个RSV季节期间对60岁及以上成人RSV相关住院的预防效果。

设计、设置和参与者：这项检测阴性病例对照研究共纳入6958名60岁及以上的成人，他们在2023年10月1日至2024年3月31日或2024年10月1日至2025年4月30日的RSV季节期间，因急性呼吸道疾病在美国20个州的26家医院住院，并在发病后10天内接受了呼吸道病毒检测。病例患者仅检测出RSV阳性；对照患者检测出RSV、SARS-CoV-2和流感阴性。通过患者访谈和电子健康记录获取人口统计学和临床数据。

暴露因素：在发病前至少14天接种一剂RSV疫苗。

主要结局和指标：使用多变量logistic回归比较住院病例和对照组中RSV疫苗接种的比值。模型调整了年龄、性别、种族和民族、地理区域以及日历月份和年份。疫苗有效性估计为（1-调整后比值比）×100%。分析按RSV疫苗接种时间（与发病相关的同季与前季）进行分层。

结果：在6958名60岁及以上的成人中，821名（11.8%）为RSV病例，6137名（88.2%）为对照组。共有1438名患者为黑人（20.1%），4314名为白人（62.0%）；3534名为女性（50.8%）。中位年龄为72岁（四分位距，66-80岁），1829名成人（26.3%）免疫功能低下。共有63名病例（7.7%）和966名对照组（15.7%）接种了疫苗。在两个季节期间，估计的RSV相关住院疫苗有效性为58%（95% CI，45%-68%），同季接种为69%（95% CI，52%-81%），而前季接种为48%（95% CI，27%-63%；P=0.06）。在两个季节期间，免疫功能低下成人（30%；95% CI，-9%至55%）的估计疫苗有效性显著低于免疫功能正常成人（67%；95% CI，53%-77%；P=0.02），有心血管疾病者（56%；95% CI，32%-72%）也显著低于无心血管疾病者（80%；95% CI，62%-90%；P=0.03）。

结论和相关性：呼吸道合胞病毒疫苗在两个季节期间预防了RSV相关住院，尽管在免疫功能低下和心血管疾病患者中的有效性低于无这些疾病的患者。需要持续监测以确定最佳的RSV再接种间隔。

### 第二部分 AI 大师评价

本研究首次系统评估了RSV疫苗在真实世界中对老年人群住院预防的长期效果，具有重要的临床指导价值。研究采用检测阴性病例对照设计，纳入6958名60岁及以上住院患者，通过多变量logistic回归分析发现疫苗在两个季节总体有效性达58%，其中同季接种效果更佳（69% vs 48%）。关键发现揭示了免疫功能低下和心血管疾病患者疫苗保护效果显著降低，为高风险人群精准接种策略提供了循证依据。研究局限性在于观察性设计可能存在的混杂偏倚，但为确定RSV疫苗再接种间隔提供了重要数据支撑。

---

速递结束，祝您工作愉快！